Looking for experience with Ibrance-Faslodex

Options

****Breastcancer.org Moderators have approved this posting. Please note that Breastcancer.org is NOT responsible for, and is not endorsing any studies.****

My name of MJ DeCoteau and I am the executive director of Rethink Breast Cancer (www.rethinkbreastcancer.com) – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.


We are looking for woman with ER+, HER2- metastatic breast cancer and women who have been treated with Ibrance (palbociclib) in combination with Faslodex (fulvestrant) to talk about their treatment experience.


The Canadian government will soon be reviewing the use of Ibrance to treat ER-positive, HER2-negative metastatic breast cancer and Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.

YOU DO NOT NEED TO LIVE IN CANADA TO PARTICIPATE.

If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/VNRHDRBY


If you would like to speak with us directly about your cancer or treatment experience, you can contact Shawna Rich-Ginsberg at shawna@rethinkbreastcancer.com.


We would also like to invite your family or friends to talk about their experience caring for a patient being treated with Ibrance: https://www.surveymonkey.com/r/VF9RRDG


MJ DeCoteau

Founder + Executive Director

Rethink Breast Cancer

Comments

  • rethink_breast_cancer
    rethink_breast_cancer Member Posts: 27
    edited September 2018

    Hi All,

    This is just a bump. We will continue to collect patient feedback for another two weeks.

    If you have been diagnosed with ER+, HER2- metastatic breast cancer or you have been treated with Ibrance (palbociclib) in combination with Faslodex (fulvestrant), please consider completing our survey.

    BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

    MJ DeCoteau

Categories